Q Fever News and Research

RSS

Huge healthcare burden of post-COVID-19 symptoms likely, suggests new study

How well do patients who had COVID-19 recover after the virus is cleared from their systems? A new preprint reports on symptom profiles over the first nine months of the illness.

13 May 2021

Scientists unveil new Ebola virus vaccine design

Scientists at Scripps Research have unveiled a new Ebola virus vaccine design, which they say has several advantages over standard vaccine approaches for Ebola and related viruses that continue to threaten global health.

13 May 2021

Investment in primary prevention can reduce rheumatic heart disease in the African Union

Rheumatic heart disease (RHD) remains a major cause of cardiovascular disease in Africa, even as acute rheumatic fever and RHD have become rare in high-income countries.

12 May 2021

Covid-19 patients show reduced gray matter volume in the brain

Covid-19 patients who receive oxygen therapy or experience fever show reduced gray matter volume in the frontal-temporal network of the brain, according to a new study led by researchers at Georgia State University and the Georgia Institute of Technology.

12 May 2021

Case study describes consequences of undetected SARS-CoV-2 infection during mRNA vaccination

Now, a new report describes a case of a coincidental mRNA vaccination and SARS-CoV-2 infection in a 31-year-old doctor, addressing the theoretical considerations for potential risks and further required actions in case more cases appear in the future.

11 May 2021

Severe COVID-19 linked to genetic clotting predisposition

Thus, the need to stratify the risk of severe or critical disease in patients presenting with SARS-CoV-2 infection remains a crying necessity. A new preprint research paper posted to the medRxiv server discusses the relationship between severe disease and pre-existing susceptibility to clots and other diseases of the cardiovascular system.

11 May 2021

FDA expands emergency use authorization for Pfizer-BioNTech COVID-19 Vaccine

Today, the U.S. Food and Drug Administration expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents 12 through 15 years of age.

10 May 2021

Natural products a rich source for novel antiviral compounds

In a recent review in the journal Viruses, researchers look at natural products that can be identified as potential alternative antiviral agents. The reviewers discussed the antiviral activities of several natural products towards DNA and RNA viruses with an analytical approach. The researchers detailed the cellular/viral targets of the active molecules and their impact on the infection and viral replication cycle.

10 May 2021

Cardiac complications found to be rare in college athletes who contracted COVID-19

In a small study, researchers found college athletes who contracted COVID-19 rarely had cardiac complications. Most had mild COVID symptoms that did not require treatment, and in a small percentage of those with abnormal cardiac testing, there was no evidence of heart damage on special imaging tests.

10 May 2021

Prevalence of SARS-CoV-2 antibodies in Germany

Seroprevalence studies have proved their worth in estimating the size and directionality of an outbreak of infectious disease, especially the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19). A new study posted to the medRxiv* preprint server describes the prevalence of SARS-CoV-2 antibodies in five representative regions of Germany.

10 May 2021

New model could help test vaccines against the deadly Strep A bacteria

Researchers have successfully developed a new Strep A human challenge model, paving the way to test vaccines against the common deadly bacteria that causes sore throats, scarlet fever and skin sores.

10 May 2021

Increased heart rate as a physiological response to SARS-CoV-2 mRNA vaccine

Although widely publicized, evidence for physiological responses to the vaccines is currently scarce in published literature. Giogiro Quer and Matteo Gadaleta of the Scripps Research Translational Institute in California, USA, led an investigation to obtain tracking data for physiological responses to vaccine programs.

8 May 2021

COVID-19 may impact the heart health of young, healthy adults

New research published in Experimental Physiology highlight the possible long term health impacts of COVID-19 on young, relatively healthy adults who were not hospitalized and who only had minor symptoms due to the virus.

7 May 2021

Researchers report encouraging results from experimental antiviral targeting Marburg virus

The Marburg virus, a relative of the Ebola virus, causes a serious, often-fatal hemorrhagic fever. Transmitted by the African fruit bat and by direct human-to-human contact, Marburg virus disease currently has no approved vaccine or antivirals to prevent or treat it.

7 May 2021

Increased symptomatic levels of COVID-19 may be associated with psychiatric symptoms

A significant level of symptoms of depression, anxiety and post-traumatic stress may follow COVID-19 independent of any previous psychiatric diagnoses, according to new research by Columbia University Mailman School of Public Health with colleagues at Universidade Municipal de São Caetano do Sul in Brazil.

7 May 2021

For Kurdish Americans in Nashville, a beloved leader’s death prompts vaccine push

On a sloppy spring day in mid-March, hundreds of Kurdish Americans gathered in a field outside Nashville, Tennessee, under a sea of black umbrellas. Some of the men carried a stretcher to an open grave, where a yellow backhoe waited.

6 May 2021

Study finds no evidence of increased risk for COVID-19 from aspirin/NSAID use

At the beginning of the pandemic, there were concerns over the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), increasing the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. NSAIDs are commonly used to treat SARS-CoV-2 infection-related symptoms such as flu and cough and are frequently taken by older adults with multiple health conditions.

6 May 2021

Pregnancy may increase the risk of COVID-19 severity

Against the background of the COVID-19 pandemic, the impact of SARS-CoV-2 infection in pregnancy has been a subject of much controversy. In order to help answer the question as to whether this infection causes significant harm in pregnancy, a new study, released as a medRxiv* preprint, reports on the disease outcomes of this infection in pregnant women.

5 May 2021

Asthma Awareness: Fighting Asthma in 2021

In light of World Asthma Day, News-Medical interviewed Dr. Samantha Walker from Asthma UK and the British Lung Foundation about fighting asthma in 2021.

5 May 2021

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021